Geode Capital Management LLC Purchases 50,579 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)

Geode Capital Management LLC grew its holdings in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 7.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 758,550 shares of the company’s stock after purchasing an additional 50,579 shares during the quarter. Geode Capital Management LLC’s holdings in Design Therapeutics were worth $4,081,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Frazier Life Sciences Management L.P. grew its stake in Design Therapeutics by 58.3% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,892,547 shares of the company’s stock valued at $10,182,000 after buying an additional 697,368 shares in the last quarter. Barclays PLC boosted its holdings in shares of Design Therapeutics by 34.2% in the third quarter. Barclays PLC now owns 96,635 shares of the company’s stock worth $520,000 after acquiring an additional 24,602 shares during the period. Point72 Asset Management L.P. grew its position in shares of Design Therapeutics by 61.6% in the third quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company’s stock valued at $8,612,000 after purchasing an additional 609,939 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in Design Therapeutics by 2.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,743,725 shares of the company’s stock worth $9,381,000 after purchasing an additional 48,431 shares in the last quarter. Finally, Paloma Partners Management Co bought a new position in Design Therapeutics in the 3rd quarter worth about $64,000. Hedge funds and other institutional investors own 56.64% of the company’s stock.

Design Therapeutics Trading Up 7.9 %

Shares of Design Therapeutics stock opened at $6.66 on Monday. The company’s 50-day moving average price is $6.05 and its 200-day moving average price is $5.17. Design Therapeutics, Inc. has a 12-month low of $2.24 and a 12-month high of $7.77. The company has a market cap of $377.10 million, a price-to-earnings ratio of -7.84 and a beta of 1.86.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.